Agreement of body adiposity index (BAI), bioimpedance analysis and ultrasound scanning in determining body fat

BACKGROUND: The steadily increasing number of people with obesity requires the development of simple and accurate methodological approaches to assess the absolute and relative amount of body fat mass. The body adiposity index (BAI) is one of the indices proposed to assess the body fat percentage. However, the comparison analysis of common methods, i.e., of bio-electrical impedance analysis and ultrasound scanning, and BAI was not performed for the Russian population.AIM: Comparison analysis of the body fat percentage estimates by bio-electrical impedance analysis, ultrasound scanning, and body adiposity index in the group of adult male and females.MATERIALS AND METHODS: An examination of healthy males and females from Moscow was conducted. Height, weight, waist and hip circumferences were measured. The body fat percentage was obtained by bio-electrical impedance analysis — BIA (ABC-02 Medas), ultrasound scanning — US (BodyMetrixTM, IntelaMetrix), and body adiposity index.RESULTS: 263 females and 134 males aged 18 to 73 years participated in the study. Correlation coefficients between BAI values and the body fat percentage obtained by BIA and US were 0.749 and 0.763 (p<0.000), respectively. Comparison of body fat percentage measurements obtained by BAI, BIA and US showed the low agreement (ССС<0.90) between BAI and other methods in pooled sample as well as in the female and male groups. Comparison of the US and BAI methods revealed higher level of agreement (ССС=0.84 [0.80–0.86]) and no systematic bias. Lower level of agreement was obtained in the group of males.CONCLUSION: Conducted study allows to conclude that, at the individual level, BAI is not an appropriate method for estimating the body fat percentage relatively to other indirect methods. However, all three methods can be used in the group of pooled males and females when testing at the population level

Possibilities of interferon induced neutropenia treatment for patients with chronic hepatitis С

The aim of our study was to estimate the effectiveness of Russian medicament Licopid to treat interferon-induced neutropenia in patients with chronic hepatitis C. The study included 21 patients with moderate and severe neutropenia during standard antiviral therapy. Genotype 1 HCV were 52.4% of patients, patients with non-genotype 1 was 47.6%. Pegylated IFN-a and ribavirin received 12 patients, standard IFN-a and ribavirin - 9 patients. Likopid was administered at a dosage of 20 mg per day for 20 days. In all patients during treatment with Likopid there was clinically meaningful and reliable growth the number of peripheral blood neutrophils to the 10th and/or 20th day of therapy. In most patients, the positive effect lasted for at least 30 days after discontinuation of the Likopid. We found that Likopid is effective regardless of genotype HCV, baseline viral load and the type of interferon. During treatment with Licopid patients had no need to take modify doses of antiviral medicine.Целью исследования явилась оценка эффективности применения отечественного препарата Ликопид, для лечения интерферон-индуцированной нейтропении у больных хроническим вирусным гепатитом С. В исследование был включен 21 пациент с нейтропенией средней и тяжелой степени на фоне стандартной противовирусной терапии. Генотип 1 вируса гепатита С имели 52,4% больных, пациенты с не 1 генотипом составили 47,6%. Лечение пегилированным ИФН-а и рибавирином получали 12 пациентов, стандартным ИФН-α и рибавирином - 9 человек. Ликопид назначался в дозировке 20 мг в сутки в течение 20 дней. У всех пациентов, на фоне лечения Ликопидом наблюдался клинически значимый и достоверный рост числа нейтрофилов периферической крови к 10-му и/или 20-му дню терапии. У большинства больных положительный эффект сохранялся по меньшей мере в течение 30 дней после отмены Ликопида. Нами установлено, что Ликопид одинаково эффективно действует у пациентов не зависимо от генотипа вируса, исходной вирусной нагрузки и типа применяемого интерферона. Во время его применения не потребовалась модификация дозы интерферона-α